Creso Pharma (ASX:CPH) has commenced the process to list on the Toronto Venture Exchange (TSX-V).
The company announced it has appointed legal counsel Aird & Berlis LLP and lead broker Echelon Wealth Partners to advise on the listing.
In February 2018, Creso finalised the acquisition of Nova Scotia-based medicinal cannabis producer, Mernova Medicinal.
The company said completion of construction of Mernova’s GMP compliant indoor facility is imminent and licensing is due to be granted in the coming months.
The Mernova facility is designed to produce three to four tonnes of its 'Ritual Green' brand of dry cannabis annually.
Creso has decided to dual list and expand its investor base into the North American market.
“With our intention to add value for our shareholders, this is an important milestone for Creso. We are pleased to offer Canadian and North American investors the opportunity to invest in a globally recognised cannabis company with a unique approach and high-quality, pharma-grade, innovative products," said Creso CEO Dr Miri Halperin Wernli.
"The Canadian market was always an ambition and given our operations in Canada, Colombia, Europe and Australia it not only makes sense but it is timely we begin this process to meet investor demand. The recent landmark legislation for full, adult-use legalisation further demonstrates Canada’s world-leading position in the cannabis industry and we look forward to reaping the benefits of this growing market.”